Howard S Hochster, MD

Professor of Medicine (Medical Oncology); Associate Director for Clinical Sciences, Yale Cancer Center; Clinical Program Leader, Gastrointestinal Cancers Program, Smilow Cancer Hospital; Clinical Research Program Leader, Gastrointestinal Cancers Program, Yale Cancer Center

Clinical Interests

  • Esophageal Neoplasms
  • Gastrointestinal Neoplasms
  • Pancreatic Neoplasms
  • Stomach Neoplasms
  • Colorectal Neoplasms

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Cancer Center, Yale: Gastrointestinal Cancer Program

Medical Oncology: Subset Medical Oncology Faculty

Yale Medical Group

Clinical Trials

Conditions Study Title
Colon E7208: A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy
Colon C80702: A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer
Colon 19F-MRS (Magnetic Resonance Spectroscopy) Studies of in-vivo 5-Fluorouracil Pharmacokinetics with and without Bevacizumab in Patients with Liver Metastases from Adenocarcinoma of the colon
Colon A Phase II Multi-center, Randomized, Placebo-Controlled Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients with Metastatic Colorectal Cancer
Esophagus Yale Gastrointestinal Cancer Biorepository
Colon, Kidney, Lung, Other Digestive Organ, Rectum, Stomach A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH BEVACIZUMAB AND/OR CHEMOTHERAPY IN PATIENTS WITH ADVANCED SOLID TUMORS
Pancreas S1313: A Phase Ib/II Randomized Study of Modified FOLFIRINOX +Pegylated Recombinant Human Hyaluronidase (PEGPH20) versus Modified FOLFIRINOX Alone in Patients with Good Performance Status Metastatic Pancreatic Adenocarcinoma.
Pancreas A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy
Colon, Rectum A double-blind, randomised, placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies.
Colon A Pilot study of the Role of Omalizumab (Xolair) in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction (HSR)
Colon, Rectum An open-label expanded access study of TAS-102 in patients with metastatic colorectal cancer refractory to or failing standard chemotherapy
Colon, Rectum S1406: Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
Breast - Female, Breast - Male, Lung, Pancreas A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Edit this profile

Contact Info

Howard S Hochster, MD
Patient Care Location
Yale Cancer CenterYale-New Haven Hospital
20 York Street, Ste North Pavilion 8

New Haven, CT 06510
Mailing Address
333 Cedar Street
Box 208028

New Haven, CT 06039

Curriculum Vitae